RT Journal Article
T1 Characteristics and management of primary and other immune thrombocytopenias: Spanish registry study.
A1 Palau, Javier
A1 Sancho, Esther
A1 Herrera, Magdalena
A1 Sanchez, Sol
A1 Mingot, Maria Eva
A1 Upegui, Rosa Isabel
A1 Rodriguez Salazar, Mª Jose
A1 de-la-Cruz, Fatima
A1 Fernandez, Mª Cristina
A1 Gonzalez-Lopez, Tomas Jose
A1 Hernandez, Jose Julio
A1 Rios, Eduardo
A1 Lopez-Fernandez, Mª Fernanda
A1 Garcia, Marta
A1 Hernandez, Jose-Angel
A1 Sanz, Miguel A
K1 Immune thrombocytopenia
K1 Corticosteroids
K1 Intravenous immunoglobulins
K1 Platelet count
K1 Response
K1 Área de Gestión Sanitaria Sur de Sevilla
AB The natural history and its modulation by treatments administered for immune thrombocytopenia (ITP) in the clinical practice remains unknown. In addition, little information is available on the characteristics and management of ITP in Spain. We conducted an observational, multicenter, registry in 70 Hematology Services from Spain between 2009 and 2011, which included children from 2 months of age and adults with primary ITP or another ITP diagnosed within the last 6 months (platelet count [PC]  484 patients were included (median [Q1, Q3] age 52 [29,74] years, 87.6% adults), 56% women, 10.5% with secondary ITP. Median (Q1, Q3) PC at diagnosis was 12 × 109/l (4, 32); 72% of patients had bleeding symptoms (62% cutaneous bleeding, 29% oral cavity bleeding, 18% epistaxis). 81% of patients with primary ITP received first-line treatment, mainly with corticosteroids (>6 weeks in 59% of cases), either alone (41%) or associated with intravenous immunoglobulin (33%). The response (≥30 × 109/L) to first-line treatment was 92%. A total of 19% of patients received second-line treatment and 6% additional treatments. At 12 months, 74% of primary ITP patients maintained a PC ≥ 100 × 109/L in absence of treatment (10% still had hemorrhagic manifestations). Characteristics of Spanish ITP patients are comparable to those from other countries. Although a high response rate to first-line treatments is observed, at 1 year, the disease persists in around one quarter of patients. Overall therapeutic management in Spain conforms to current recommendations, except for an excessive duration of corticosteroids therapy.
PB Taylor & Francis
YR 2017
FD 2017-04-17
LK http://hdl.handle.net/10668/11101
UL http://hdl.handle.net/10668/11101
LA en
NO Palau J, Sancho E, Herrera M, Sánchez S, Mingot ME, Upegui RI, et al. Characteristics and management of primary and other immune thrombocytopenias: Spanish registry study. Hematology. 2017 Sep;22(8):484-492
DS RISalud
RD Apr 10, 2025